In vitro activity of apramycin against 16S-RMTase-producing Gram-negative isolates.

RNA, Ribosomal, 16S / genetics Anti-Bacterial Agents / pharmacology Aminoglycosides / pharmacology Nebramycin / pharmacology Escherichia coli
16S rRNA methyltransferases AAC(3)-IV Aminoglycosides ArmA Gram-negative bacilli RmtB

Journal

Journal of global antimicrobial resistance
ISSN: 2213-7173
Titre abrégé: J Glob Antimicrob Resist
Pays: Netherlands
ID NLM: 101622459

Informations de publication

Date de publication:
06 2023
Historique:
received: 17 11 2022
revised: 10 01 2023
accepted: 02 02 2023
medline: 20 6 2023
pubmed: 24 2 2023
entrez: 23 2 2023
Statut: ppublish

Résumé

Apramycin is an aminoglycoside (AG) with a unique structure that is little affected by plasmid-mediated mechanisms of AG resistance, including most AG-modifying enzymes and 16S rRNA methyltransferases (16S-RMTases). We evaluate the activity of apramycin against a collection of 16S-RMTase-producing isolates, including Enterobacterales, non-fermenting bacteria, and carbapenemase producers. In total, 164 non-duplicate 16S-RMTase-producing isolates, including 84 Enterobacterales, 53 Acinetobacter baumannii and 27 Pseudomonas aeruginosa isolates, were included in the study. Whole-genome sequencing (WGS) was performed on all isolates with Illumina technology. The minimum inhibitory concentration (MIC) of apramycin was determined by broth microdilution with customized Sensititre plates (Thermo Fisher Scientific, Dardilly, France). We found that 95% (156/164) of the 16S-RMTase-producing isolates were susceptible to apramycin, with a MIC Resistance to apramycin remains rare in 16S-RMTase-producing isolates. Apramycin may, therefore, be an interesting alternative treatment for infections caused by 16S-RMTase and carbapenemase producers.

Identifiants

DOI: 10.1016/j.jgar.2023.02.005 PMID: 36822368
pubmed: 36822368
pii: S2213-7165(23)00018-8
doi: 10.1016/j.jgar.2023.02.005
pii:
doi:

Substances chimiques

apramycin 388K3TR36Z
RNA, Ribosomal, 16S 0
Anti-Bacterial Agents 0
Aminoglycosides 0
Nebramycin 11048-13-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

21-25

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest None declared

Auteurs

François Caméléna (F)

Department of Bacteriology, Saint-Louis-Lariboisière Hospital Group, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris Cité, INSERM 1137, IAME, Paris, France.

Mathilde Liberge (M)

Department of Bacteriology, Saint-Louis-Lariboisière Hospital Group, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris Cité, INSERM 1137, IAME, Paris, France.

Inès Rezzoug (I)

Department of Bacteriology, Saint-Louis-Lariboisière Hospital Group, Assistance Publique-Hôpitaux de Paris, Paris, France.

Manel Merimèche (M)

Department of Bacteriology, Saint-Louis-Lariboisière Hospital Group, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris Cité, INSERM 1137, IAME, Paris, France.

Thierry Naas (T)

Department of Bacteriology-Hygiene, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicêtre, France; Université de Paris-Saclay, INSERM 1184, RESIST Unit, Le Kremlin-Bicêtre, France; French National Reference Centre for Antimicrobial Resistance, Le Kremlin-Bicêtre, France.

Béatrice Berçot (B)

Department of Bacteriology, Saint-Louis-Lariboisière Hospital Group, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris Cité, INSERM 1137, IAME, Paris, France. Electronic address: beatrice.bercot@aphp.fr.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Management of the infected total elbow arthroplasty.

Joaquin Sanchez-Sotelo
1.00
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents

Comparative genomic analysis and characterization of novel high-quality draft genomes from the coal metagenome.

Arunmozhi Bharathi Achudhan, Lilly M Saleena
1.00
Coal Metagenome Phylogeny Bacteria Genome, Bacterial

Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants.

Papon Thamvasupong, Kwanchanok Viravaidya-Pasuwat
1.00
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Classifications MeSH

questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN ribosomique › ARN ribosomique 16S › In vitro activity of apramycin against...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › In vitro activity of apramycin against...
questionsmedicales.fr › Glucides › Hétérosides › Aminosides › In vitro activity of apramycin against...
questionsmedicales.fr › Glucides › Hétérosides › Aminosides › Kanamycine › Nébramycine › In vitro activity of apramycin against...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Escherichia › Escherichia coli › In vitro activity of apramycin against...